Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile ...

Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today presented preclinical data for REX-8756 ...
Nasdaq

Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...
Nasdaq

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 ...
MedCity News

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The drugmaker is ...
MM&M

Sanofi goes oral route in Recludix deal to develop tailored I&I drugs

Sanofi inked a deal to co-develop and commercialize oral anti-inflammatory drugs resulting from Recludix Pharma’s STAT6 platform technology. STAT6 (signal transducer and activator of transcription 6), ...

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical ...
BioWorld

STAT6 degradation of IL-4/13: preclinical data in atopic dermatitis

In allergic diseases, STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways and the key driver of Th2 inflammation. Because STAT6 functions through protein-protein and ...
BioWorld

Recludix and Sanofi collaborate on oral STAT6 inhibitors for immunological and inflammatory diseases

Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6 ...